On March 5, 2026 Quanta Therapeutics, a privately held, clinical-stage biopharmaceutical company leading the development of innovative oral therapeutics for RAS-driven cancers, reported the presentation of data demonstrating its oral multi-KRAS inhibitors, G12D-preferring QTX3034 and G12V-preferring QTX3544, retain potent activity in the presence of known and novel mechanisms acquired from treatment with the pan-RAS(ON) tri-complex inhibitor, daraxonrasib. The presentation will be given at the AACR (Free AACR Whitepaper) Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics being held March 5-8, 2026, in Los Angeles, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"While pan-RAS tri-complex inhibitors have demonstrated a broad potential to treat various KRAS-driven cancers, acquired resistance mechanisms have limited the depth and durability of clinical benefit, particularly with heterogeneous tumors such as colorectal cancer," said Cameron Pitt, PhD, Co-Founder and Chief Operating Officer of Quanta Therapeutics. "Our data confirm previously reported resistance pathways, identify novel mutations uniquely associated with this class of therapies and demonstrate the ability of our drug candidates to overcome key tri-complex inhibitor resistance mechanisms."

Pitt added, "As the field continues to evolve, patients with KRAS-mutated cancers will require multiple distinct drug mechanisms to combat the propensity for RAS reactivation. Studies like this deepen our understanding of resistance biology and can inform strategies to optimize patient outcomes. Supported by encouraging clinical data to date, along with these new preclinical findings, we believe our approach to direct KRAS inhibition may provide a valuable therapeutic option for KRAS-mutant cancer patients with diverse treatment histories including a prior tri-complex inhibitor."

AACR-RAS presentation information:
Title: Resistance to the pan-RAS(ON) tri-complex inhibitor daraxonrasib is overcome by direct multi- KRAS inhibitors, QTX3034 and QTX3544.
Date and Time: Saturday, March 7, 2026; 11:45 am – 12:15 pm
Session Name: Poster Session B
Abstract Number: B033

(Press release, Quanta Therapeutics, MAR 5, 2026, View Source [SID1234663317])